MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1β through the MEK-Erk1/2 and Jak/Stat3 Pathways

Figure 6

Effects of GDC0623 and C188-9 on MEK-Erk1/2 and Jak-Stat3 signaling pathways and on expression levels of MMP9 and MMP13. Osteoblasts were pretreated with DMEM plus 0.1% FBS overnight and intervened with IL-1β, IL-1β plus GDC0623, and IL-1β plus C188-9 for 60 min. (a–c) Protein levels of p-Stat3, P-Erk1/2, MMP9, and MMP13 were analyzed after IL-1β-stimulated osteoblasts had been treated with GDC0623. (d–f) Expression levels of p-Stat3, P-Erk1/2, MMP9, and MMP13 were assessed by blocking the Jak-Stat3 pathway with C188-9.

(a)

(b)

(c)

(d)

(e)

(f)